Chen P, Liu Y, Wen Y, Zhou C (2022) Non-small cell lung cancer in China. Cancer Commun (Lond) 42(10):937–970

Article  PubMed  Google Scholar 

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A et al (2022) Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(5): pp. 497–530

Nagasaka M, Gadgeel SM (2018) Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther 18(1):63–70

Article  CAS  PubMed  Google Scholar 

Lei X, Li T, Mao F, Ren F, Tang Q, Cao W et al (2023) Lobe-specific analysis of perioperative chemotherapy for non-small cell lung cancer patients. Cancer Med 12(16):16896–16905

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA et al (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, Non-Small-Cell lung Cancer. Clin Lung Cancer 19(1):58–64

Article  CAS  PubMed  Google Scholar 

Phillips I, Stares M, Allan L, Sayers J, Skipworth R, Laird B (2022) Optimising outcomes in Non small cell lung cancer: targeting Cancer cachexia. Front Biosci (Landmark Ed) 27(4):129

Article  CAS  PubMed  Google Scholar 

Baudino TA (2015) Targeted Cancer therapy: the next generation of Cancer treatment. Curr Drug Discov Technol 12(1):3–20

Article  CAS  PubMed  Google Scholar 

Hong M, Shi H, Wang N, Tan HY, Wang Q, Feng Y (2019) Dual effects of Chinese herbal medicines on angiogenesis in Cancer and ischemic stroke treatments: role of HIF-1 network. Front Pharmacol 10:696

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang C, Li L, Fu D, Qin T, Ran Y, Xu F et al (2019) Discovery of chalcone-modified estradiol analogs as antitumour agents that inhibit tumour angiogenesis and epithelial to mesenchymal transition. Eur J Med Chem 176:135–148

Article  CAS  PubMed  Google Scholar 

McLachlan J, Banerjee S (2015) Pazopanib in ovarian cancer. Expert Rev Anticancer Ther 15(9):995–1005

Article  CAS  PubMed  Google Scholar 

Sandler A (2007) Bevacizumab in Non small cell lung cancer. Clin Cancer Res, 13(15 Pt 2): p. s4613-6.

Chu TQ, Chen JH, Han BH (2018) [Current progression of bevacizumab in advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 40(10):793–800

CAS  PubMed  Google Scholar 

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550

Article  CAS  PubMed  Google Scholar 

Petrioli R, Francini E, Fiaschi AI, Laera L, Luzzi L, Paladini P et al (2015) Switch maintenance treatment with oral Vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study. Med Oncol 32(4):134

Article  PubMed  Google Scholar 

Chen L, Yin Y, Liu C, Liu J, Zheng M, Tang Y et al (2024) Metformin alleviates bevacizumab-induced vascular endothelial injury in mice through growth differentiation factor 15 upregulation. Iran J Basic Med Sci 27(3):343–351

CAS  PubMed  PubMed Central  Google Scholar 

Pollak MN (2012) Investigating Metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2(9):778–790

Article  CAS  PubMed  Google Scholar 

Marrone KA, Zhou X, Forde PM, Purtell M, Brahmer JR, Hann CL et al (2018) A randomized phase II study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in patients with Chemotherapy-Naive advanced or metastatic nonsquamous Non-Small cell lung Cancer. Oncologist 23(7):859–865

Article  CAS  PubMed  PubMed Central  Google Scholar 

in 2019 exceptional surveillance of lung cancer: diagnosis and management (NICE guideline NG122).(2019):London

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

Article  CAS  PubMed  Google Scholar 

Bhattarai A, Shah S, Abu Serhan H, Sah R, Sah S (2023) Genomic profiling for non-small cell lung cancer: clinical relevance in staging and prognosis. Med (Baltim) 102(47):e36003

Article  CAS  Google Scholar 

Jang S, Zheng C, Tsai HT, Fu AZ, Barac A, Atkins MB et al (2016) Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. Cancer 122(1):124–130

Article  CAS  PubMed  Google Scholar 

Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM (2014) Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: Understanding and managing a new syndrome. Can J Cardiol 30(5):534–543

Article  PubMed  Google Scholar 

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: avail. J Clin Oncol 27(8):1227–1234

Article  CAS  PubMed  Google Scholar 

Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A et al (2016) Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis. Cancer Sci 107(12):1837–1842

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S et al (2015) A randomized, Double-Blind, placebo-Controlled, multicenter, phase III study of First-Line Carboplatin/Paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous Non-Small-Cell lung Cancer. J Clin Oncol 33(19):2197–2204

Article  CAS  PubMed  Google Scholar 

Han S, Hong Y, Liu T, Wu N, Ye Z (2018) The efficacy and safety of Paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Oncotarget 9(18):14619–14629

Article  PubMed  Google Scholar 

Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH et al (2013) Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 24(1):20–30

Article  PubMed  Google Scholar 

Lima AB, Macedo LT, Sasse AD (2011) Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE 6(8):e22681

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen N, Ren M, Li R, Deng X, Li Y, Yan K et al (2015) Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma. Mol Cancer 14:140

Article  PubMed  PubMed Central  Google Scholar 

Nakaya A, Kurata T, Yokoi T, Iwamoto S, Torii Y, Katashiba Y et al (2016) Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer. Cancer Med 5(7):1381–1387

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iliopoulos D, Hirsch HA, Struhl K (2011) Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71(9):3196–3201

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O’Reilly MS et al (2013) Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002–1009

Article  CAS  PubMed  Google Scholar 

Li Y, Gappy S, Liu X, Sassalos T, Zhou T, Hsu A et al (2022) Metformin suppresses pro-inflammatory cytokines in vitreous of diabetes patients and human retinal vascular endothelium. PLoS ONE 17(7):e0268451